U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C22H29NO2
Molecular Weight 339.4712
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of A-834735

SMILES

CC1(C)C(C(=O)C2=CN(CC3CCOCC3)C4=CC=CC=C24)C1(C)C

InChI

InChIKey=NQTMRZNYLIGQCF-UHFFFAOYSA-N
InChI=1S/C22H29NO2/c1-21(2)20(22(21,3)4)19(24)17-14-23(13-15-9-11-25-12-10-15)18-8-6-5-7-16(17)18/h5-8,14-15,20H,9-13H2,1-4H3

HIDE SMILES / InChI

Molecular Formula C22H29NO2
Molecular Weight 339.4712
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

A-834735 is a drug developed by Abbott Laboratories, acts as a potent cannabinoid receptor full agonist at both the CB1 and CB2 receptors.

CNS Activity

Curator's Comment: Known to be CNS active in rat. Human data not available

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P21554|||Q5UB37
Gene ID: 1268.0
Gene Symbol: CNR1
Target Organism: Homo sapiens (Human)
4.6 nM [Ki]
Target ID: P34972
Gene ID: 1269.0
Gene Symbol: CNR2
Target Organism: Homo sapiens (Human)
0.31 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
PubMed

PubMed

TitleDatePubMed
Indol-3-ylcycloalkyl ketones: effects of N1 substituted indole side chain variations on CB(2) cannabinoid receptor activity.
2010 Jan 14
Patents

Sample Use Guides

in rats: To benchmark imaging data against potential CNS side effects of A-834735 using traditional in vivo behaviour assays, rotarod performance and spontaneous exploratory behaviour were assessed in naive rats. Each rat was given three training sessions and then rotorod performance (mean latency to fall from the rotorod) was determined 30 min following i.p. administration of vehicle or A-834735 (0.5, 1.5 or 5 μmol kg−1). For spontaneous exploratory behaviour, a total of 40 rats (n=8 per group) were injected i.p. with vehicle (5% dimethyl sulphoxide/PEG400) or A-834735 (0.5, 1.5, 5 and 15 μmol kg−1) in a volume of 2 ml kg−1 and returned to their home cages.
Route of Administration: Intraperitoneal
Doses of A-834735 that produce CB1-mediated changes in brain activity detected by phMRI produce sufficient brain concentrations to bind CB1 and CB2 receptors and induce a functional effect, as predicted by in vitro Ki and EC50 data in binding and cAMP assays. A-834735 acts as a full agonist at both the central CB1 and peripheral CB2 receptors in rat with Ki values of 4.6 and 0.31 nM, respectively and EC50 values of 12 and 0.21 nM, respectively.
Substance Class Chemical
Created
by admin
on Sat Dec 16 10:25:24 UTC 2023
Edited
by admin
on Sat Dec 16 10:25:24 UTC 2023
Record UNII
XE27L67C93
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
A-834735
Code English
(1-(TETRAHYDROPYRAN-4-YLMETHYL)-1H-INDOL-3-YL)-(2,2,3,3-TETRAMETHYLCYCLOPROPYL)METHANONE
Systematic Name English
METHANONE, (1-((TETRAHYDRO-2H-PYRAN-4-YL)METHYL)-1H-INDOL-3-YL)(2,2,3,3-TETRAMETHYLCYCLOPROPYL)-
Systematic Name English
A834,735
Code English
(1-((TETRAHYDRO-2H-PYRAN-4-YL)METHYL)-1H-INDOL-3-YL)-(2,2,3,3-TETRAMETHYLCYCLOPROPYL)METHANONE
Systematic Name English
Code System Code Type Description
PUBCHEM
11544639
Created by admin on Sat Dec 16 10:25:24 UTC 2023 , Edited by admin on Sat Dec 16 10:25:24 UTC 2023
PRIMARY
CAS
895155-57-4
Created by admin on Sat Dec 16 10:25:24 UTC 2023 , Edited by admin on Sat Dec 16 10:25:24 UTC 2023
PRIMARY
WIKIPEDIA
A-834,735
Created by admin on Sat Dec 16 10:25:24 UTC 2023 , Edited by admin on Sat Dec 16 10:25:24 UTC 2023
PRIMARY
FDA UNII
XE27L67C93
Created by admin on Sat Dec 16 10:25:24 UTC 2023 , Edited by admin on Sat Dec 16 10:25:24 UTC 2023
PRIMARY
EPA CompTox
DTXSID60468349
Created by admin on Sat Dec 16 10:25:24 UTC 2023 , Edited by admin on Sat Dec 16 10:25:24 UTC 2023
PRIMARY
Related Record Type Details
ACTIVE MOIETY
MRI Imaging studies with SD rats
IN-VIVO
Scientific Literature
ACTIVE MOIETY
Cannabinoid 1 receptor (CB1) and Cannabinoid 2 receptor (CB2) agonist; Ki=0.21 nM (Human CB2) & 12 nM (Human CB1)
IN-VITRO
Ki